{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T12:01:50Z","timestamp":1757592110796},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ucl.2024.03.013","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T04:05:32Z","timestamp":1716005132000},"page":"347-354","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overview of Systemic Therapies in Penile Cancer"],"prefix":"10.1016","volume":"51","author":[{"given":"Chiara","family":"Mercinelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majd","family":"Al Assaad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houssein","family":"Safa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jad","family":"Chahoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2024.03.013_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ucl.2024.03.013_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2022.04.020","article-title":"Patient reported outcomes in advanced penile cancer","volume":"40","author":"Youssef","year":"2022","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.013_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/iju.15346","article-title":"Differences in overall survival of penile cancer patients versus population-based controls","volume":"31","author":"Scheipner","year":"2023","journal-title":"Int J Urol"},{"key":"10.1016\/j.ucl.2024.03.013_bib4","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.urology.2010.04.008","article-title":"Prognostic Factors in Penile Cancer","volume":"76","author":"Ficarra","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2024.03.013_bib5","first-page":"68","article-title":"Contemporary management of regional nodes in penile cancer - Improvement of survival?","volume":"191","author":"Djajadiningrat","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2024.03.013_bib6","author":"Flaig"},{"key":"10.1016\/j.ucl.2024.03.013_bib7","unstructured":"EAU-ASCO Penile Cancer Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6."},{"key":"10.1016\/j.ucl.2024.03.013_bib8","article-title":"Management of Lymph Node\u2013positive Penile Cancer: A Systematic Review","author":"Sachdeva","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2024.03.013_bib9","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2024.03.013_bib10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clgc.2015.07.009","article-title":"A\u00a0Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings","volume":"14","author":"Nicolai","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ucl.2024.03.013_bib11","first-page":"1147","article-title":"Systematic Review and Meta-Analysis - Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma?","volume":"203","author":"Azizi","year":"2020","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2024.03.013_bib12","unstructured":"Rose KM, Pham R, Zacharias NM, et al. Neoadjuvant Platinum-Based Chemotherapy and Lymphadenectomy for Penile Cancer: An International, Multi-Institutional, Real-World Study. doi:10.1093\/jnci\/djae034\/7608613."},{"key":"10.1016\/j.ucl.2024.03.013_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.05.008","article-title":"Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study","volume":"33","author":"Sharma","year":"2015","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"key":"10.1016\/j.ucl.2024.03.013_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/j.1464-410X.2012.11453.x","article-title":"Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis","volume":"110","author":"Di Lorenzo","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2024.03.013_bib15","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.urology.2010.03.002","article-title":"Diagnosis and staging of penile cancer","volume":"76","author":"Heyns","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2024.03.013_bib16","article-title":"Trends in Incidence, Mortality, and Survival of Penile Cancer in the United States: A Population-Based Study","volume":"12","author":"Deng","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ucl.2024.03.013_bib17","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.urology.2010.03.082","article-title":"Treatment of visceral, unresectable, or bulky\/unresectable regional metastases of penile cancer","volume":"76","author":"Pettaway","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2024.03.013_bib18","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/bjc.2013.620","article-title":"Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK\/09\/001)","volume":"109","author":"Nicholson","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ucl.2024.03.013_bib19","doi-asserted-by":"crossref","first-page":"32212","DOI":"10.18632\/oncotarget.4802","article-title":"Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ucl.2024.03.013_bib20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.urology.2014.12.049","article-title":"Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes","volume":"85","author":"Wang","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2024.03.013_bib21","first-page":"541","article-title":"Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: Implications for selection of systemic therapy","volume":"201","author":"Jacob","year":"2019","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2024.03.013_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOU.0000000000000941","article-title":"Innovative systemic therapies for penile cancer","volume":"32","author":"Chahoud","year":"2022","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.ucl.2024.03.013_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clgc.2015.08.001","article-title":"Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed","volume":"14","author":"Necchi","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ucl.2024.03.013_bib24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/CAD.0b013e328350ead7","article-title":"Combination of docetaxel and cetuximab for penile cancer: A case report and literature review","volume":"23","author":"Rescigno","year":"2012","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ucl.2024.03.013_bib25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bju.14013","article-title":"First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study","volume":"121","author":"Necchi","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2024.03.013_bib26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bju.15828","article-title":"First-line programmed death receptor-1 (PD-1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum-based chemotherapy, for stage IV penile cancer","volume":"131","author":"Yan","year":"2023","journal-title":"BJU Int"},{"issue":"16_Suppl","key":"10.1016\/j.ucl.2024.03.013_bib27","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1200\/JCO.2022.40.16_suppl.5037","article-title":"Anti-EGFR antibody plus anti-PD-1 antibody and chemotherapy as a neoadjuvant regimen for patients with locally-advanced penile squamous cell carcinoma: A prospective, single-arm, single-center, phase II clinical trial","volume":"40","author":"An","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2024.03.013_bib28","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3390\/cancers13102323","article-title":"Assessment of pi3k\/mtor\/akt pathway elements to serve as biomarkers and therapeutic targets in penile cancer","volume":"13","author":"Thomas","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ucl.2024.03.013_bib29","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/cancers14071683","article-title":"Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer","volume":"14","author":"Thomas","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ucl.2024.03.013_bib30","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1200\/JCO.20.01652","article-title":"Phase I Study of Cabozantinib and Nivolumab Alone or with Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2024.03.013_bib31","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41467-020-15980-9","article-title":"Effective combinatorial immunotherapy for penile squamous cell carcinoma","volume":"11","author":"Huang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ucl.2024.03.013_bib32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ucl.2024.03.013_bib33","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1186\/s12885-022-10432-7","article-title":"Increased HRD score in cisplatin resistant penile cancer cells","volume":"22","author":"Winkelmann","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ucl.2024.03.013_bib34","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2024.03.013_bib35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s12967-021-03073-0","article-title":"Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer","volume":"19","author":"Meng","year":"2021","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.ucl.2024.03.013_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1470-2045(18)30682-X","article-title":"Prevalence of human papillomavirus DNA and p16 INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis","volume":"20","author":"Olesen","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ucl.2024.03.013_bib37","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eururo.2015.12.007","article-title":"Role of Human Papillomavirus in Penile Carcinomas Worldwide","volume":"69","author":"Alemany","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2024.03.013_bib38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1158\/1940-6207.CAPR-14-0284","article-title":"Genomic profiling of human penile carcinoma predicts worse prognosis and survival","volume":"8","author":"Busso-Lopes","year":"2015","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.ucl.2024.03.013_bib39","article-title":"Prognostic significance of P16INK4a expression in penile squamous cell carcinoma: A meta-analysis with trial sequential analysis","volume":"2018","author":"Zhang","year":"2018","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ucl.2024.03.013_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1615\/CritRevOncog.2020032961","article-title":"The role of oncogenic DNA viruses in penile cancer development","volume":"24","author":"da Rocha","year":"2019","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.ucl.2024.03.013_bib41","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/v9090254","article-title":"Immunopathogenesis of HPV-associated cancers and prospects for immunotherapy","volume":"9","author":"Smola","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.ucl.2024.03.013_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tranon.2016.10.005","article-title":"Prognostic value of tumor-infiltrating lymphocytes for patients with head and neck squamous cell carcinoma","volume":"10","author":"Xu","year":"2017","journal-title":"Transl Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2024.03.013_bib43","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.48002","article-title":"Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden","volume":"6","author":"Necchi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ucl.2024.03.013_bib44","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","article-title":"The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix","volume":"27","author":"Maciag","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ucl.2024.03.013_bib45","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: A first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2024.03.013_bib46","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/jitc-2020-001395","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus-associated malignancies","volume":"8","author":"Strauss","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.ucl.2024.03.013_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112981","article-title":"Phase Ib\/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers","volume":"191","author":"Borcoman","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ucl.2024.03.013_bib48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients with Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ucl.2024.03.013_bib49","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.97.15.8501","article-title":"Activation of p53 in cervical carcinoma cells by small molecules","volume":"97","author":"Hietanen","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ucl.2024.03.013_bib50","doi-asserted-by":"crossref","first-page":"46163","DOI":"10.18632\/oncotarget.17575","article-title":"5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression","volume":"8","author":"Morel","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ucl.2024.03.013_bib51","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1158\/1078-0432.CCR-17-3119","article-title":"CDK9 inhibitor FIT-039 suppresses viral oncogenes E6 and E7 and has a therapeutic effect on HPV-induced neoplasia","volume":"24","author":"Ajiro","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2024.03.013_bib52","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2024.03.013_bib53","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2024.03.013_bib54","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1349-7006.2003.tb01499.x","article-title":"Nectins and nectin-like molecules: Roles in cell adhesion, migration, and polarization","volume":"94","author":"Takai","year":"2003","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ucl.2024.03.013_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2022.12.008","article-title":"An Analysis of Nectin-4 (PVRL4) in Penile Squamous Cell Carcinoma","volume":"49","author":"Grass","year":"2023","journal-title":"European Urology Open Science"},{"key":"10.1016\/j.ucl.2024.03.013_bib56","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab Vedotin: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ucl.2024.03.013_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113360","article-title":"The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy","volume":"194","author":"Tan","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ucl.2024.03.013_bib58","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: Regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ucl.2024.03.013_bib59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.humpath.2023.10.003","article-title":"Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma","volume":"142","author":"Tekin","year":"2023","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.ucl.2024.03.013_bib60","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-20-4004","article-title":"Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma","volume":"27","author":"Chahoud","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7_Suppl","key":"10.1016\/j.ucl.2024.03.013_bib61","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/JCO.2019.37.7_suppl.505","article-title":"Penile squamous cell carcinoma is genomically similar to other HPV-driven tumors","volume":"37","author":"Chahoud","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2024.03.013_bib62","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA -Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N\u00a0Engl J Med"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014324000387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014324000387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T02:52:31Z","timestamp":1719283951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014324000387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0094014324000387"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2024.03.013","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of Systemic Therapies in Penile Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2024.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}